Human papillomavirus infection: Protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)
Macey L. Murray, Jade Meadows, Caroline J. Doré, Andrew J. Copas, Lewis J. Haddow, Charles Lacey, Mark Jit, Katherine Soldan, Kate Bennett, Michelle Tetlow, Mayura Nathan, Richard Gilson*
Research output: Contribution to journal › Article › peer-review
24Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Human papillomavirus infection: Protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)'. Together they form a unique fingerprint.